Norman Ng: Advocating for an Independent Cancer Drug Formulary and Faster Approvals
Norman Ng, Director of Patient Advocacy and Public Affairs of Healthcare Thinkers, shared on LinkedIn:
“Advocate for Sin Chew to establish an independent cancer drug list
At the end of last year, the HA improved the new drug mechanism, shortening the time for new drugs to be included in the drug formulary by half. Tang hopes that the registration and approval of new drugs can be ‘divided into two teams’ to approve cancer drugs separately, so that patients can benefit from the new drugs more quickly.
Lung cancer patient Ng Lok Man, convener of the Lung Cancer Patient Concern Group, hopes that the authorities can refer to Singapore and other places to formulate an independent cancer drug formulary, and at the same time review medical financing, such as following the example of the mainland to launch the ‘Huimin Insurance’ with low premiums and high sum insured.”
More posts featuring Norman Ng.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023